Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print August 14, 2003, 10.1148/radiol.2291021383
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zakian, K. L.
Right arrow Articles by Koutcher, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zakian, K. L.
Right arrow Articles by Koutcher, J. A.

Transition Zone Prostate Cancer: Metabolic Characteristics at 1H MR Spectroscopic Imaging—Initial Results1

Kristen L. Zakian, PhD, Steven Eberhardt, MD, Hedvig Hricak, MD, PhD, Amita Shukla-Dave, PhD, Shanon Kleinman, BS, Manickam Muruganandham, PhD, Kanishka Sircar, MD, Michael W. Kattan, PhD, Victor E. Reuter, MD, Peter T. Scardino, MD and Jason A. Koutcher, MD, PhD

1 From the Departments of Medical Physics (K.L.Z., A.S.D., S.K., M.M., J.A.K.), Radiology (K.L.Z., S.E., H.H., J.A.K.), Pathology (K.S., V.E.R.), Urology (M.W.K., P.T.S.), Epidemiology and Biostatistics (M.W.K.), and Medicine (J.A.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Received October 28, 2002; revision requested December 12; revision received January 15, 2003; accepted February 28. Supported by National Institutes of Health grants R21 CA 84258-01 and 7-R01 CA76423. Address correspondence to K.L.Z. (e-mail: zakiank@mskcc.org).



View larger version (17K):

[in a new window]
 
Figure 1. Scatterplot depicts average metabolite ratios for 16 patients in cancerous TZ regions (Ca) and benign control regions.

 


View larger version (134K):

[in a new window]
 
Figure 2a. MR imaging/MR spectroscopic imaging data and pathology section in a 51-year-old patient (patient 5) with a large left-sided TZ tumor. The patient also had a small tumor in the right side of the PZ. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor (T) in dashed region. (b) Spectral grid corresponding to a shows metabolite levels. T and dashed lines indicate tumor regions. (c) Whole-mount pathology step section shows tumor regions (outlined).

 


View larger version (42K):

[in a new window]
 
Figure 2b. MR imaging/MR spectroscopic imaging data and pathology section in a 51-year-old patient (patient 5) with a large left-sided TZ tumor. The patient also had a small tumor in the right side of the PZ. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor (T) in dashed region. (b) Spectral grid corresponding to a shows metabolite levels. T and dashed lines indicate tumor regions. (c) Whole-mount pathology step section shows tumor regions (outlined).

 


View larger version (160K):

[in a new window]
 
Figure 2c. MR imaging/MR spectroscopic imaging data and pathology section in a 51-year-old patient (patient 5) with a large left-sided TZ tumor. The patient also had a small tumor in the right side of the PZ. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor (T) in dashed region. (b) Spectral grid corresponding to a shows metabolite levels. T and dashed lines indicate tumor regions. (c) Whole-mount pathology step section shows tumor regions (outlined).

 


View larger version (135K):

[in a new window]
 
Figure 3a. MR imaging/MR spectroscopic imaging data and pathology section in a 56-year-old patient (patient 8) with glandular BPH, stromal BPH, and TZ tumor. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor, which is indicated by dashed line. G = glandular BPH, S = stromal BPH. (b) Subgrid of spectra corresponding to the black rectangular region in a. G = glandular BPH, S = stromal BPH. (c) Pathology step section corresponding most closely to a shows tumor regions (outlined).

 


View larger version (30K):

[in a new window]
 
Figure 3b. MR imaging/MR spectroscopic imaging data and pathology section in a 56-year-old patient (patient 8) with glandular BPH, stromal BPH, and TZ tumor. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor, which is indicated by dashed line. G = glandular BPH, S = stromal BPH. (b) Subgrid of spectra corresponding to the black rectangular region in a. G = glandular BPH, S = stromal BPH. (c) Pathology step section corresponding most closely to a shows tumor regions (outlined).

 


View larger version (104K):

[in a new window]
 
Figure 3c. MR imaging/MR spectroscopic imaging data and pathology section in a 56-year-old patient (patient 8) with glandular BPH, stromal BPH, and TZ tumor. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor, which is indicated by dashed line. G = glandular BPH, S = stromal BPH. (b) Subgrid of spectra corresponding to the black rectangular region in a. G = glandular BPH, S = stromal BPH. (c) Pathology step section corresponding most closely to a shows tumor regions (outlined).

 


View larger version (131K):

[in a new window]
 
Figure 4a. MR imaging/MR spectroscopic imaging data obtained in the same patient as in Figure 3 but at a more inferior location. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor (T) surrounded by dashed line. (b) Subgrid of spectra corresponding to the black rectangular region in a. T = tumor. (c) Pathology step section corresponding most closely to a shows tumor regions (outlined).

 


View larger version (32K):

[in a new window]
 
Figure 4b. MR imaging/MR spectroscopic imaging data obtained in the same patient as in Figure 3 but at a more inferior location. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor (T) surrounded by dashed line. (b) Subgrid of spectra corresponding to the black rectangular region in a. T = tumor. (c) Pathology step section corresponding most closely to a shows tumor regions (outlined).

 


View larger version (117K):

[in a new window]
 
Figure 4c. MR imaging/MR spectroscopic imaging data obtained in the same patient as in Figure 3 but at a more inferior location. (a) MR spectroscopic imaging grid superimposed on transverse T2-weighted MR image obtained with 1,000/130, PRESS volume excitation with BASING water and lipid suppression, 16 x 8 x 8 chemical shift imaging, a 100 x 50 x 50-mm field of view, 6.25-mm resolution, one signal acquired, and a 17-minute imaging time shows tumor (T) surrounded by dashed line. (b) Subgrid of spectra corresponding to the black rectangular region in a. T = tumor. (c) Pathology step section corresponding most closely to a shows tumor regions (outlined).

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2003 by the Radiological Society of North America.